
CUREVAC
the RNA people®
CureVac's mRNA based Vaccine Candidate against SARS-CoV-2
Data update September 24th, 2020
- STRICTLY CONFIDENTIAL -

Project update: Recent Ph1 and hamster results are encouraging and dose escalation continues in order to select the final dose

Previously shared, with data as of September 28th

CureVac's mRNA platform and pre-clinical data

CVnCoV Clinical Development Plan and available clinical data

Manufacturing footprint and delivery plan

CVnCoV presentation and target shelf-life at 2-8°C

Focus of today's update

1. Update on available Phase 1 data
   - Reactogenicity profile at higher doses
   - IgG titers at higher doses
   - VNTs across the dose range: methodology improvements suggest that dose should be at least 8µg, and require continuing exploration towards higher doses before final dose selection for pivotal trials
2. Hamster data suggest that CVnCoV has the potential to protect lung disease and reduce viral load in nose and throat
3. Clinical development plan supported by EMA feedback
4. Progress on manufacturing network and updated capacity estimates at higher doses

1. Update on available Phase 1 clinical data: reactogenicity and immunogenicity


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


(10)(1c)


2. Insights from animal model data
CUREVAC
the RNA people®

Hamster Challenge Model: ELISA responses are detectable after 1st dose and Virus Neutralizing Titers after 2nd dose in Hamsters

Binding antibodies (ELISA)

VNTs (CPE based)



High VNTs after 2 vaccinations at 10 µg



Encoded protein: SARS-CoV-S full length $K_{986}P$, $V_{987}P$

Evaluation: ELISA IgG & **VNTs**: Cytopathic effect (CPE) based microneutralization at Viroclinics

CVnCoV is able to decrease viral levels in the throat



Viral loads in throat

Dose dependent reduction of viral loads in the throat following 2 vaccinations at 2µg and 10µg



Evaluation: : live virus titration from throat swaps

CVnCoV Provides Protection of the Lungs and Leads to Reduced Viral Titers in Nasal Turbinates





Evaluation: live virus titration from lung and nasal turbinates homogenates

Viral loads in lungs and nasal turbinates

All animals show protection of the lungs comparable to infected positive control at 10 µg

Trend for reduced nasal viral loads in 3 out of 5 animals at 10µg



Lung Protection of CVnCoV - Reduced Percentage of Affected Lung Tissue Upon Challenge Infection

Gross lung pathology at day 7 after challenge
% affected lung pathology



Lung protection - no evidence of Enhanced Disease: Reduced gross lung pathology compared to the control groups



3. Clinical development plan supported by EMA feedback

CVnCoV - Progress and path towards EMA approval

✓	**Jan 2020**	**Design** of multiple vaccine candidates
✓	**Mar 2020**	Lead candidate **selection** out of several candidates
✓	**Jun 2020**	**GMP production** of lead candidate
✓	**Jun 2020**	CTA approval and **start of Phase 1** clinical trial
✓	**Aug 2020**	**CTA approval of Phase 2a** clinical trial in older adults
	Oct 2020	**Ph1 data** (safety and immunogenicity) - **final dose selection**
	Oct 2020	**CTA submission for Phase 2b/3**
	Q1 2021	**EMA submission** based on safety (n~3,500), immunogenicity and preliminary efficacy.
	Q1/2 2021	Projected **Conditional Marketing Approval** (EMA)
	Q3/4 2021	Projected **Full Marketing Approval** (EMA)

+1 month if need to increase to 16µg or 20µg

CUREVAC the RNA people


(10)(1c)

5. Progress on manufacturing network and updated capacity estimates


(10)(1c)


(10)(1c)


CUREVAC
the RNA people®
CureVac AG
Friedrich-Miescher-Strasse 15
72076 Tübingen, Germany
T +49 7071 9883-0
www.curevac.com
RNActive® RNArt® RNAdjuvant® PureMessenger® RNAntigen® RNAntibody® RNAnimal® CVCM® The RNA Printer®